Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Investigating causal relations between sleep traits and risk of breastcancer in women: mendelian randomisation study. To examine whether sleep traits have a causal effect on risk of breast cancer.Mendelian randomisation study.UK Biobank prospective cohort study and BreastCancer Association Consortium (BCAC) case-control genome-wide association study.156 848 women in the multivariable regression and one sample mendelian randomisation (MR) analysis in UK Biobank (7784 with a breastcancer (...) diagnosis) and 122 977 breastcancer cases and 105 974 controls from BCAC in the two sample MR analysis.Self reported chronotype (morning or evening preference), insomnia symptoms, and sleep duration in multivariable regression, and genetic variants robustly associated with these sleep traits.Breast cancer diagnosis.In multivariable regression analysis using UK Biobank data on breastcancer incidence, morning preference was inversely associated with breastcancer (hazard ratio 0.95, 95% confidence
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for BreastCancer. The use of adjuvant chemotherapy in patients with breastcancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breastcancer recurrence adds prognostic information to the recurrence score is not known.We performed a prospective trial involving 9427 women with hormone-receptor-positive, human epidermal (...) growth factor receptor 2-negative, axillary node-negative breastcancer, in whom an assay of 21 genes had been performed, and we classified the clinical risk of recurrence of breastcancer as low or high on the basis of the tumor size and histologic grade. The effect of clinical risk was evaluated by calculating hazard ratios for distant recurrence with the use of Cox proportional-hazards models. The initial endocrine therapy was tamoxifen alone in the majority of the premenopausal women who were 50
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive BreastCancer Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive BreastCancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO (...) .19.00945 Journal of Clinical Oncology - published online before print May 31, 2019 PMID: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive BreastCancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx , MD, PhD 1 x Fabrice Andre ; , MD 2 x Nofisat Ismaila ; , MD, PhD 3 x N. Lynn Henry ; , PhD 2 x Mark R. Somerfield ; , MD 4 x Robert C. Bast ; , PhD 5 x William Barlow ; 6 x Deborah E. Collyar ; , MD 7 x M. Elizabeth Hammond
Impact of Breast Surgery in Primary Metastasized BreastCancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial Conflicting evidence exists regarding the value of surgical resection of the primary in stage IV breastcancer patients.The prospective randomized phase III ABCSG-28 POSYTIVE trial evaluated median survival comparing primary surgery followed by systemic therapy to primary systemic therapy in de novo stage IV breast cancer.Between 2011 and 2015, 90 previously (...) untreated stage IV breastcancer patients were randomly assigned to surgical resection of the primary tumor followed by systemic therapy (Arm A) or primary systemic therapy (Arm B) in Austria. Overall survival (OS) was defined as the primary study endpoint.The trial was stopped early due to poor recruitment. Ninety patients (45 arm A, 45 arm B) were included; median follow-up was 37.5 months. Patients in the surgery arm had more cT3 breastcancer (22.2% vs 6.7%) and more cN2 staging (15.6% vs 4.4
Phthalate Exposure and BreastCancer Incidence: A Danish Nationwide Cohort Study Phthalate exposure is ubiquitous and especially high among users of drug products formulated with phthalates. Some phthalates mimic estradiol and may promote breastcancer. Existing epidemiologic studies on this topic are small, mostly not prospective, and have given inconsistent results. We estimated associations between longitudinal phthalate exposures and breastcancer risk in a Danish nationwide cohort, using (...) then fit multivariable Cox regression models to estimate associations between phthalate exposures and incident invasive breast carcinoma according to tumor estrogen receptor status.Over 9.99 million woman-years of follow-up, most phthalate exposures were not associated with breastcancer incidence. High-level dibutyl phthalate exposure (≥ 10,000 cumulative mg) was associated with an approximately two-fold increase in the rate of estrogen receptor-positive breastcancer (hazard ratio, 1.9; 95% CI, 1.1
Early BreastCancer: ESMO Clinical Practice Guidelines 1 Early breastcancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † F. Cardoso 1 , S. Kyriakides 2 , S. Ohno 3 , F. Penault-Llorca 4,5 , P. Poortmans 6, 7 , I. T. Rubio 8 , S. Zackrisson 9 and E. Senkus 10 , on behalf of the ESMO Guidelines Committee* 1 Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; 2 Europa Donna Cyprus, Nicosia, Cyprus; 3 Breast Oncology Center, Cancer (...) , Poland. *Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano Switzerland. E-mail: firstname.lastname@example.org † Approved by the ESMO Guidelines Committee: August 2003, last update April 2019. This publication supersedes the previously published version—Ann Oncol 2015; 26 (Suppl. 5): v8- v30. For the purpose of the ESMO guidelines, inoperable locally advanced breastcancer is considered part of advanced breastcancer (ABC) and is discussed in the ABC guidelines
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced BreastCancer. PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breastcancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies.In a randomized, phase 3 trial, we compared alpelisib (at a dose of 300 mg per day) plus fulvestrant (at a dose of 500 mg every 28 days and once on day 15 (...) ) with placebo plus fulvestrant in patients with HR-positive, HER2-negative advanced breastcancer who had received endocrine therapy previously. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. The primary end point was progression-free survival, as assessed by the investigator, in the cohort with PIK3CA-mutated cancer; progression-free survival was also analyzed in the cohort without PIK3CA-mutated cancer. Secondary end points included overall response
Breastcancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. To investigate the incidence and characteristics of breastcancer in transgender people in the Netherlands compared with the general Dutch population.Retrospective, nationwide cohort study.Specialised tertiary gender clinic in Amsterdam, the Netherlands.2260 adult trans women (male sex assigned at birth, female gender identity) and 1229 adult trans men (female sex assigned at birth (...) , male gender identity) who received gender affirming hormone treatment.Incidence and characteristics (eg, histology, hormone receptor status) of breastcancer in transgender people.The total person time in this cohort was 33 991 years for trans women and 14 883 years for trans men. In the 2260 trans women in the cohort, 15 cases of invasive breastcancer were identified (median duration of hormone treatment 18 years, range 7-37 years). This was 46-fold higher than in cisgender men (standardised
Perspectives on Conversations About Costs of Cancer Care of BreastCancer Survivors and Cancer Center Staff: A Qualitative Study. Despite recommendations to discuss the cost of care (CoC) with patients with cancer, little formal guidance is available on how to conduct these sensitive conversations in ways that are acceptable to both patients and providers.To explore the perspectives of patients and medical and nonmedical cancer center staff on CoC conversations.In individual interviews (...) , participants were asked to discuss the content of, timing of, and ideal person to hold CoC conversations. Interviews were transcribed verbatim. Content was analyzed to identify emerging essential elements.Division of Preventive Medicine, University of Alabama at Birmingham.42 women aged 60 to 79 years with a history of breastcancer and 20 cancer center staff (6 physicians, 4 nurses, 5 patient navigators, 3 social workers, and 2 billing specialists).Both patients and providers identified reassurance
Abemaciclib (Verzenios) For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breastcancer in combination with fulvestrant as initial endocrine-based therap 1 1 SMC2179 abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) Eli Lilly and Company 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life process abemaciclib (Verzenios®) is accepted for restricted use within NHSScotland. Indication under review: For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breastcancer in combination with fulvestrant* as initial endocrine-based therapy
Abemaciclib (Verzenios) Women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breastcancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based t 1 Published 13 May 2019 1 SMC2135 abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) Eli Lilly and Company 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards (...) and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission abemaciclib (Verzenios®) is accepted for use within NHSScotland. Indication under review: for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breastcancer in combination with an aromatase inhibitor* as initial endocrine-based therapy, or in women who have
10-year performance of four models of breastcancer risk: a validation study Independent validation is essential to justify use of models of breastcancer risk prediction and inform decisions about prevention options and screening. Few independent validations had been done using cohorts for common breastcancer risk prediction models, and those that have been done had small sample sizes and short follow-up periods, and used earlier versions of the prediction tools. We aimed to validate (...) the relative performance of four commonly used models of breastcancer risk and assess the effect of limited data input on each one's performance.In this validation study, we used the BreastCancer Prospective Family Study Cohort (ProF-SC), which includes 18 856 women from Australia, Canada, and the USA who did not have breastcancer at recruitment, between March 17, 1992, and June 29, 2011. We selected women from the cohort who were 20-70 years old and had no previous history of bilateral prophylactic
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early BreastCancer The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breastcancer (EBC).Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC
Risk-reducing medications for primary breastcancer: a network meta-analysis. Breastcancer is the most frequently occurring malignancy and the second cause of death for cancer in women. Cancer prevention agents (CPAs) are a promising approach to reduce the burden of breastcancer. Currently, two main types of CPAs are available: selective estrogen receptor modulators (SERMs, such as tamoxifen and raloxifene) and aromatase inhibitors (AIs, such as exemestane and anastrozole).To assess (...) the efficacy and acceptability of single CPAs for the prevention of primary breastcancer, in unaffected women, at an above-average risk of developing breast cancer.Using a network meta-analysis, to rank single CPAs, based on their efficacy and acceptability (an endpoint that is defined as the inverse of CPA-related toxicity).We searched the Cochrane BreastCancer Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, World Health Organization's International
Screening for BreastCancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. The purpose of this guidance statement is to provide advice to clinicians on breastcancer screening in average-risk women based on a review of existing guidelines and the evidence they include.This guidance statement is derived from an appraisal of selected guidelines from around the world that address breastcancer screening, as well as their included evidence. All national (...) is all clinicians, and the target patient population is all asymptomatic women with average risk for breast cancer.In average-risk women aged 40 to 49 years, clinicians should discuss whether to screen for breastcancer with mammography before age 50 years. Discussion should include the potential benefits and harms and a woman's preferences. The potential harms outweigh the benefits in most women aged 40 to 49 years.In average-risk women aged 50 to 74 years, clinicians should offer screening
Accuracy of Self-Report for Cervical and BreastCancer Screening Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and BreastCancer Screening Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and BreastCancer Screening Health Services Research & Development Management eBrief no. 152 » Issue 152 April 2019 (...) The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Brief: Accuracy of Self-Report for Cervical and BreastCancer Screening Guideline-based breast and cervical cancer screening are considered essential health benefits and are fundamental components of high-quality primary care services in the United States. The aim of cancer screening is to identify cancers in an early stage when treatment is more likely to be effective. Accurate measurement of cancer screening rates is vital
Screening for BreastCancer in Average-Risk Women ACP Guidance Statement on BreastCancer Screening in Average-Risk Women | Annals of Internal Medicine | American College of Physicians '); } '); })(); Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register and create your Annals account INSTITUTIONAL SIGN IN | | Subscribe to Annals of Internal Medicine . You will be directed to acponline.org to complete your purchase (...) . Search Clinical Guidelines | 16 April 2019 Screening for BreastCancer in Average-Risk Women: A Guidance Statement From the American College of Physicians Free Amir Qaseem, MD, PhD, MHA; Jennifer S. Lin, MD, MCR; Reem A. Mustafa, MD, MPH, PhD; Carrie A. Horwitch, MD, MPH; Timothy J. Wilt, MD, MPH; for the Clinical Guidelines Committee of the American College of Physicians Amir Qaseem, MD, PhD, MHA American College of Physicians, Philadelphia, Pennsylvania (A.Q.) Jennifer S. Lin, MD, MCR Kaiser